Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement
By J. Moon, D. Messroghli, Peter Kellman, S. Piechnik, M. Robson, M. Ugander, P. Gatehouse, A. Arai, M. Friedrich, S. Neubauer and 2 more. Journal of Cardiovascular Magnetic Resonance, 2013
1,042 citations recorded by the source corpus.
Rapid innovations in cardiovascular magnetic resonance (CMR) now permit the routine acquisition of quantitative measures of myocardial and blood T1 which are key tissue characteristics. These capabilities introduce a new frontier in cardiology, enabling the practitioner/investigator to quantify biologically important myocardial properties that otherwise can be difficult to ascertain clinically. CMR may be able to track biologically important changes in the myocardium by: a) native T1 that reflects myocardial disease involving the myocyte and interstitium without use of gadolinium based contrast agents (GBCA), or b) the extracellular volume fraction (ECV)–a direct GBCA-based measurement of the size of the extracellular space, reflecting interstitial disease. The latter technique attempts to dichotomize the myocardium into its cellular and interstitial components with estimates expressed as volume fractions. This document provides recommendations for clinical and research T1 and ECV measurement, based on published evidence when available and expert consensus when not. We address site preparation, scan type, scan planning and acquisition, quality control, visualisation and analysis, technical development. We also address controversies in the field. While ECV and native T1 mapping appear destined to affect clinical decision making, they lack multi-centre application and face significant challenges, which demand a community-wide approach among stakeholders. At present, ECV and native T1 mapping appear sufficiently robust for many diseases; yet more research is required before a large-scale application for clinical decision-making can be recommended.
Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/dd4ebf240bb05d23dd957d07c67872b83c7c4000
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review (2016, methodology): “Thus, reports on T1 values should always include the T1 mapping technique that was used and the site-specific normal range for T1 [11].”
- Magnetic resonance multitasking for motion-resolved quantitative cardiovascular imaging (2018, neutral): “…(NMR) relaxation constants T 1 and T 2 is promising for cardiovascular tissue characterization, revealing fibrosis, oedema, inflammation, and more 1, 2 ; quantification of myocardial blood flow (MBF) through myocardial perfusion imaging is promising for diagnosing ischemia and coronary artery…”
- Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI) (2017, background): “compartment (including the myocardial vasculature) [2].”
- Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. (2018, methodology): “, modified Look-Locker inversion recovery [MOLLI], shortened modified Look-Locker inversion recovery [ShMOLLI]), saturation recovery (saturation recovery single-shot acquisition [SASHA]), or hybrid methods (44).”
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, neutral): “In addition, CMR allows the characterization of myocardial tissue of myocarditis, amyloidosis, sarcoidosis, Chagas disease, Fabry disease non-compaction cardiomyopathy and haemochromatosis.(91,101,103,104) CMR may also be used for the assessment of myocardial ischaemia and viability in patients with”
- T1-mapping in the heart: accuracy and precision (2014, background): “Changes in both native T1 and T1 following administration of gadolinium (Gd) based contrast agents are considered important biomarkers and multiple methods have been suggested for quantifying myocardial T1 in vivo [1].”